Resources
-
Tech Transfer Challenges and How to Avoid Common Mistakes
Roundtable Notes: Session 2 Table 17 WCBP 2025
Tech Transfer Challenges and How to Avoid Common Mistakes -
Setting Specifications on Limited Data, Clinically
Relevant Specs/ Next Generation Control Strategies: Looking Ahead to Revision of ICH
Q6B
Roundtable Notes: Session 1 Table 1 WCBP 2025
Setting Specifications on Limited Data, Clinically Relevant Specs/ Next Generation Control Strategies: Looking Ahead to Revision of ICH Q6B -
Setting Specification (Including Potency) for Not Well-Characterized Biological Products, e.g., Cell and Gene Therapy Products [Session 2]
Roundtable Notes: Session 2 Table 1 WCBP 2025
Setting Specification (Including Potency) for Not Well-Characterized Biological Products, e.g., Cell and Gene Therapy Products [Session 2] -
Relevance of Accelerated and Forced Degradation Studies for a Frozen DS DP [Session 1]
Roundtable Notes: Session 1 Table 6 WCBP 2025
Relevance of Accelerated and Forced Degradation Studies for a Frozen DS DP [Session 1] -
Relevance of Accelerated and Forced Degradation Studies for a Frozen DS DP [Session 2]
Roundtable Notes: Session 2 Table 6 WCBP 2025
Relevance of Accelerated and Forced Degradation Studies for a Frozen DS DP [Session 2] -
Recent Trends in Questions from Global Health Authorities [Session 1]
Roundtable Notes: Session 1 Table 3 WCBP 2025
Recent Trends in Questions from Global Health Authorities [Session 1] -
Recent Trends in Questions from Global Health Authorities [Session 2]
Roundtable Notes: Session 2 Table 3 WCBP 2025
Recent Trends in Questions from Global Health Authorities [Session 2] -
Practical Applications of AI and ML in Discovery, Development and Platform Establishment Including CQA Controls
Roundtable Notes: Session 1 Table 13 WCBP 2025
Practical Applications of AI and ML in Discovery, Development and Platform Establishment Including CQA Controls -
Navigating 2-Tier Reference Standard Strategy for Biologics
Roundtable Notes: Session 1 Table 12 WCBP 2025
Navigating 2-Tier Reference Standard Strategy for Biologics -
Moving Away from Animal Testing and Animal Derived Components Including Alternate Endotoxin Test [Session 2]
Roundtable Notes: Session 2 Table 4 WCBP 2025
Moving Away from Animal Testing and Animal Derived Components Including Alternate Endotoxin Test [Session 2] -
Moving Away from Animal Testing and Animal Derived Components Including Alternate Endotoxin Test [Session 1]
Roundtable Notes: Session 1 Table 4 WCBP 2025
Moving Away from Animal Testing and Animal Derived Components Including Alternate Endotoxin Test [Session 1] -
Microbiological Submission Roadblocks
Roundtable Notes: Session 2 Table 10 WCBP 2025
Microbiological Submission Roadblocks -
Molecule-Independent Device Bridging Approach (MIDBA) – a Novel Proposed Methodology for the Clinical Validation of Subcutaneous Device Platforms
Roundtable Notes: Session 1 Table 16 WCBP 2025
Molecule-Independent Device Bridging Approach (MIDBA) – a Novel Proposed Methodology for the Clinical Validation of Subcutaneous Device Platforms -
Method Transfer Challenges at CMOs CROs
Roundtable Notes: Session 2 Table 13 WCBP 2025
Method Transfer Challenges at CMOs CROs -
Managing/Leveraging CMOs and CTOs for Lifecycle Success [Session 2]
Roundtable Notes: Session 2 Table 7 WCBP 2025
Managing/Leveraging CMOs and CTOs for Lifecycle Success [Session 2] -
Host Cell Protein Assays- Are We Still Relying on Conventional Quantification by Enzyme-Linked Immunosorbent Assays (ELISAs)
Roundtable Notes: Session 2 Table 16 WCBP 2025
Host Cell Protein Assays- Are We Still Relying on Conventional Quantification by Enzyme-Linked Immunosorbent Assays (ELISAs) -
Global Access to Medicines in Underserved Regions
Roundtable Notes: Session 1 Table 18 WCBP 2025
Global Access to Medicines in Underserved Regions -
Fix-Dose Co-Formulated Protein Product in Liquid or Solid
Roundtable Notes: Session 1 Table 11 WCBP 2025
Fix-Dose Co-Formulated Protein Product in Liquid or Solid -
CMC Challenges with Complex Formulations - Excipient Selection and Impact on Product Stability and Process Consistency
Roundtable Notes: Session 1 Table 2 WCBP 2025
CMC Challenges with Complex Formulations - Excipient Selection and Impact on Product Stability and Process Consistency -
CMC Challenges with Complex Formulations
Roundtable Notes: Session 2 Table 2 WCBP 2025
CMC Challenges with Complex Formulations